SPHK1 and cancer: While modulation of immunosuppression in the TME suggests a potential therapeutic benefit for SphK inhibition as part of the armament against cancer, we recently discovered a previously unrecognized role for sphingolipids as regulators of cancer cell immunogenicity [2].